Artivion (AORT) Projected to Post Quarterly Earnings on Thursday

Artivion (NYSE:AORT) is projected to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of $0.0088 per share and revenue of $119.9920 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Artivion Trading Down 1.9%

NYSE:AORT opened at $26.94 on Wednesday. Artivion has a 52-week low of $19.16 and a 52-week high of $48.25. The company has a quick ratio of 2.80, a current ratio of 3.86 and a debt-to-equity ratio of 0.48. The stock has a fifty day simple moving average of $23.27 and a 200-day simple moving average of $31.40. The company has a market capitalization of $1.31 billion, a PE ratio of 112.26 and a beta of 1.25.

Analyst Ratings Changes

Several research firms have weighed in on AORT. Citigroup restated a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Weiss Ratings downgraded shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 8th. Stifel Nicolaus set a $45.00 price target on shares of Artivion in a research report on Monday, June 1st. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $36.00 price objective on shares of Artivion in a research note on Tuesday, June 16th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Artivion has a consensus rating of “Moderate Buy” and an average target price of $44.17.

Insider Activity at Artivion

In other news, SVP Andrew M. Green sold 44,001 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the transaction, the senior vice president owned 60,259 shares of the company’s stock, valued at $1,247,361.30. The trade was a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is currently owned by company insiders.

Institutional Trading of Artivion

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd acquired a new position in Artivion in the 3rd quarter valued at $27,000. Smartleaf Asset Management LLC lifted its stake in shares of Artivion by 47.7% during the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after purchasing an additional 538 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in shares of Artivion during the fourth quarter worth $79,000. Quadrant Capital Group LLC acquired a new stake in shares of Artivion during the third quarter worth $92,000. Finally, iSAM Funds UK Ltd purchased a new stake in shares of Artivion in the third quarter valued at $131,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.